Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
Akcea shareholders approved the transaction on April 16 at a Special Meeting of Stockholders
Ionis licenses Akcea worldwide rights to inotersen and AKCEA-TTR-LRx
CAMBRIDGE, Mass. and CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the two companies have completed a previously announced transaction licensing the exclusive, worldwide rights from Ionis to Akcea for inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx.
Inotersen is under regulatory review in the U.S. and EU with approvals planned for mid-2018 for the treatment of hereditary transthyretin amyloidosis, or hATTR. hATTR is a systemic, progressive and fatal disease. Akcea and Ionis are also developing AKCEA-TTR-LRx for hereditary and wild-type forms of ATTR and plan to commence clinical studies for AKCEA-TTR-LR in 2018.
In addition, following the close of the transaction, today, Sarah Boyce joined Akcea as president and a member of the Akcea board of directors reporting to Paula Soteropoulos, Akcea's chief executive officer. Ms. Boyce was formerly the chief business officer at Ionis.
The transaction was subject to certain closing conditions, including a non-waivable condition that the stock purchase agreement, the license agreement and related agreements and the transaction be approved by the affirmative vote of holders representing a majority of the issued and outstanding shares of common stock other than Ionis and its affiliates, which excluded a vote of Akcea's directors and officers. This affirmative vote was obtained at a special meeting of Akcea stockholders on April 16, 2018.
Under the agreement, Akcea paid Ionis an upfront licensing fee of $150 million through the issuance of 8,000,000 shares of common stock priced at $18.75 per share. Akcea obtained rights to commercialize inotersen and AKCEA-TTR-LRx globally. To support the incremental resources required for the launch of inotersen and to progress the clinical development program for ACKEA-TTR-LRx, Ionis purchased $200 million of Akcea common stock, or 10,666,666 shares, priced at $18.75 per share. Upon closing this transaction, Ionis' ownership in Akcea increased by 7%, from 68% to 75%, totaling 64,114,545 shares. Regulatory approval of inotersen and AKCEA-TTR-LRx in the U.S. and EU will trigger milestone payments to Ionis of $50 million and $40 million, respectively, for each drug, with additional milestone payments due upon approval of both programs in various other geographies. The initial milestone payments may be payable in Akcea common stock at fair market value. Commercial profits and losses from inotersen will be split 60% to Ionis and 40% to Akcea until the first commercial sale of AKCEA-TTR-LRx, after which the profits and losses will be shared 50/50. The costs of the development of AKCEA-TTR-LRx and the profits from its commercialization will be shared 50/50. The license for the two drugs also includes various sales milestone payments of up to nearly $1.3 billion. For this transaction, Ionis was advised by Stifel, Nicolaus & Company, Incorporated and Akcea was advised by Cowen and Company, LLC.
Inotersen is an antisense drug designed to reduce the production of transthyretin, or TTR protein, to treat TTR amyloidosis (ATTR), a systemic, progressive and fatal disease.
Inotersen is currently under regulatory review for marketing authorization in the U.S. and EU. The U.S. Food and Drug Administration has granted Orphan Drug Designation and Fast Track Status to inotersen and the European Medicines Agency has granted Orphan Drug Designation to inotersen.
ABOUT HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (hATTR)
hATTR is a progressive, systemic, and fatal genetic disease caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs throughout the body, including in peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to sensory, motor and autonomic dysfunction often having debilitating effects on multiple aspects of a patient's life. Patients with hATTR often present with a mixed phenotype and experience overlapping symptoms of polyneuropathy and cardiomyopathy.
Ultimately, hATTR results in death within three to fifteen years of symptom onset. Therapeutic options for the treatment of patients with hATTR are limited and there are currently no disease-modifying drugs approved for hATTR. There are an estimated 50,000 patients with hATTR worldwide.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over 40 drugs in development. SPINRAZA® (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Inotersen and volanesorsen are two antisense drugs that Ionis discovered and successfully advanced through Phase 3 studies. Inotersen is under regulatory review for marketing approval in the U.S. and EU for the treatment of patients with hereditary ATTR amyloidosis. Volanesorsen is under regulatory review for marketing approval in the U.S., EU and Canada for the treatment of patients with familial chylomicronemia syndrome, or FCS. Volanesorsen is also in a Phase 3 study in patients with familial partial lipodystrophy, or FPL. Akcea, an affiliate of Ionis focused on developing and commercializing drugs to treat patients with serious and rare diseases, will commercialize inotersen and volanesorsen, if approved. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including inotersen, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology. Inotersen is under regulatory review in the U.S. and EU for the treatment of hereditary transthyretin amyloidosis (hATTR). Volanesorsen is under regulatory review in the U.S., EU and Canada for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Cambridge, Massachusetts. Additional information about Akcea is available at www.akceatx.com.
IONIS' AND AKCEA'S FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the recently announced transaction between Ionis and Akcea, Ionis' and Akcea's business and the therapeutic and commercial potential of inotersen, AKCEA-TTR-LRx and other products in development. Any statement describing Ionis' or Akcea's goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of inotersen, volanesorsen or other of Ionis' or Akcea's drugs in development is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' and Akcea's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' and Akcea's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis and Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' and Akcea's programs are described in additional detail in Ionis' and Akcea's annual reports on Form 10-K for the year ended December 31, 2017, which are on file with the SEC. Copies of these and other documents are available from each company.
In this press release, unless the context requires otherwise, "Ionis", "Akcea," "Company," "Companies" "we," "our," and "us" refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals(TM) is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics(TM) is a trademark of Akcea Therapeutics, Inc.
Akcea Media and Investor Contact:
Head of Communications and Investor Relations
Ionis Media and Investor Contact:
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Akcea Therapeutics, Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Forterra Announces First Quarter 2018 Earnings Schedule24.4.2018 12:00 | Pressmeddelande
IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release first quarter 2018 financial results before the market open on Tuesday, May 8, 2018. A conference call to review financial results will also be held on Tuesday, May 8, 2018 at 8:30 a.m. Eastern time (7:30 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Charlie Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q1 2018 Forterra, Inc. Earnings Call Date: Tuesday, May 8, 2018 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) https://edge.media-server.com/m6/p/a3wzhe79 Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Participant Passcode: 6398379 Replay Information A replay of the conference call and archive of the webcast will be available within 24 hours after the call on the "Events & Presentations" page under the Investor section of the Company's w
Meltwater acquires leading social analytics company Sysomos24.4.2018 10:00 | Pressmeddelande
Acquisition expands Meltwater's ability to incorporate online news and data with social media analytics in one robust platform SAN FRANCISCO, April 24, 2018 (GLOBE NEWSWIRE) -- Meltwater, a pioneer of media intelligence and now Outside Insight, today announced its acquisition of Sysomos, a leader in social analytics and engagement. The addition of Sysomos to Meltwater enables organizations to analyze social media, news and other human-generated content in one platform, furthering Meltwater's mission to give businesses the insights from outside data, helping them stay ahead. "All the social analytics companies look at social data in isolation, limiting the insights for brands and businesses," says Jorn Lyseggen, founder and CEO of Meltwater. "With our acquisition of Sysomos, we can bring together news and social media under one company, giving social data context while adding social engagement to our news and media monitoring offering." For the PR and communications teams who engage wit
New leaders emerge in 2018 All-Europe trading team ranking24.4.2018 10:00 | Pressmeddelande
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Competition in electronic trading is becoming fierce as global trade execution teams re-position themselves for delivering their solutions at scale in a post MiFID II regulatory environment. J.P. Morgan continues to dominate claiming first place in electronic trading, for a second consecutive year, according to Institutional Investor's All-Europe Trading Team survey. Meanwhile Bank of America Merrill Lynch took home second place, up two spots from fourth place last year; a significant move for Bank of America Merrill Lynch, which bumped its peers Credit Suisse in third place and UBS in fourth place to win the No. 2 position. The two-rung move is a marked shift away from its previous high-touch leadership and is an endorsement that the bank's investments in technology are resonating with clients. In high-touch trading, UBS leapt to No. 1 swapping its fifth place position last year with Bank of America Merrill Lynch, who took fifth in the high
BT Dials in Corvil Analytics to Help Achieve World-Class Service Delivery for World's Largest Virtual Contact Centre24.4.2018 10:00 | Pressmeddelande
Corvil empowers BT with the visibility and insight to achieve outstanding caller experience for a public sector customer serving 20M+ citizens DUBLIN, Ireland, April 24, 2018 (GLOBE NEWSWIRE) -- Corvil today announced that BT Global Services has deployed Corvil Analytics to manage and optimise VoIP call quality of one of the largest contact centres in the world channelling its services through 30,000 agents across 180 sites. As a leading provider of contact centre solutions globally, BT has a strong track-record in designing and implementing large-scale transformational engagements. Looking to simplify service assurance and maintain call quality excellence in an environment where call volumes continually reach 12500 concurrent calls (12 new calls per second), BT sought to enlist an analytics partner. In a climate of intense scrutiny on public sector performance and with stringent customer Service Level Agreements (SLAs) in place, BT selected Corvil to help improve caller experience by
MedicCoin Unveils International Adoption Strategy Based on Integrating Blockchain Technology into Everyday Life24.4.2018 09:00 | Pressmeddelande
Strategy focuses on improving health of mankind through blockchain-powered rewards, advancing scientific research and charitable donations NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- MedicCoin, a community-driven crypto focused on improving the lives of millions worldwide, today provides the multifaceted roadmap established for global adoption while recapping practical innovations that set MedicCoin apart for everyday use. Introducing Multiple Ways to Earn Crypto as a Reward for Positive Choices The MedicCoin founders envisioned using blockchain technology to make life better for all mankind. A key part of staying true to this vision is ensuring people around the world can join the MedicCoin community without highly technical skills or expensive mining equipment. Living an Active Lifestyle By simply installing the MedicWalk app and staying active, anyone will be able to acquire MedicCoin. MedicWalk will be launched within the next few weeks. Donating Unused Computer
In-Memory Computing Summit Europe Announces Full Breakout Session Schedule24.4.2018 09:00 | Pressmeddelande
Register by April 29th to Receive a 30 Percent Discount FOSTER CITY, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- GridGain Systems, provider of enterprise-grade in-memory computing platform solutions based on Apache® Ignite(TM), today released the full breakout session schedule for the second annual In-Memory Computing Summit® Europe, the premier conference for individuals from Europe and Asia that are currently using or exploring using in-memory computing. Conference breakout sessions are in five tracks: Tales from the Trenches, New Capabilities, Architecture, Streaming Data, and Hardware. Speakers include representatives from companies such as Oracle, Intel, NEC Corporation of America, GridGain Systems, Hazelcast, iguazio, Neeve Research, ScaleOut Software, Software AG, Bouquet.ai, and VoltDB. The IMC Summit Europe will take place at the Park Plaza Victoria London, June 25-26, 2018. Attendees can receive a 30 percent Super Saver discount off the full price registration fee by purchasin
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum